SCHEMBL23926372

SCHEMBL23926372

Cc1ccc(O)c(-c2nc(-c3cccc(C)c3O)n3c2CCCC3)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 12/20 0.37
ALDH1A1 P00352 3/20 0.32
LMNA P02545 2/20 0.32
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
THRB P10828 1/20 0.32
TGFBR1 P36897 1/20 0.32
MAPK14 Q16539 1/20 0.32
KDM4E B2RXH2 2/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
GAA P10253 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
USP2 O75604 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TP53 P04637 1/20 0.31
GRM5 P41594 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30118934 1.00 RORC (0.37) RORCALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL23926341 0.89 RORC (0.38) RORCMAPTTHRBTGFBR1MAPK14
SCHEMBL30118929 0.89 RORC (0.38) RORCMAPTTHRBTGFBR1MAPK14
SCHEMBL30118953 0.87 KDM4E (0.41) RORCALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL23926351 0.87 KDM4E (0.41) RORCALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL23926377 0.85 KDM4E (0.38) RORCMAPTTHRBTGFBR1MAPK14
SCHEMBL30118924 0.85 KDM4E (0.38) RORCMAPTTHRBTGFBR1MAPK14
SCHEMBL23926379 0.83 KDM4E (0.39) ALDH1A1LMNAMAPTL3MBTL1THRB
SCHEMBL30118895 0.83 KDM4E (0.39) ALDH1A1LMNAMAPTL3MBTL1THRB
SCHEMBL23926361 0.81 ALDH1A1 (0.37) RORCALDH1A1LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168408-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-04-26 EP disclosed
CN-115667256-A Compounds for treating diseases and methods of treating diseases 艾特里提治疗有限公司 2023-01-31 CN disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 RORC 1253/4885ALDH1A1 2721/4885LMNA 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.